Fintan Walton, founder and CEO of PharmaVentures chairs a round table discussion on this pressing issue.   Featuring; Jim Gale. Managing Partner, Signet Healthcare Partners. A New York based Private equity firm with a wide portfolio including API medchem, Pharma Services and CDMO businesses. Andreas Raabe: Founder & CEO of Adragos Pharma, a CDMO manufacturing in the EU and Japan. Frank Dollard: 45 years of experience in pharmaceutical manufacturing, including GSK, BMS and Teva. Soren Demin: Managing Director & Head of M&A at PharmaVentures and formerly senior commercial positions in multiple pharma business and a qualified medical practitioner.   In a wide-ranging discussion, hear the panelist's views on; What is meant by "drug shortages" and where has the system failed? Where are the pinch points; manufacture, supply chains, pharma-centric influences, geopolitical events? The impact on manufacturers of the US Biosecure Act. The knock-on effects of pricing pressure on raw material sourcing. Increasing capacity & the role of M&A Can technology and innovation solve the problems? Where are the opportunities emerging from that will provide the solutions?